Circulating Tumor Cells Inc is categorized under Commercial Biotechnical Research in San Jose, CA and active since 2004.
Circulating Tumor Cells Inc was established in 2004, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Carl Hull at the company’s single location by writing to 120 Baytech Drive, San Jose, California CA 95134 or by phoning (408) 719-6400. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Circulating Tumor Cells Inc |
| Contact Person: | Carl Hull |
| Address: | 120 Baytech Drive, San Jose, California 95134 |
| Phone Number: | (408) 719-6400 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2004 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Circulating Tumor Cells Inc was started in 2004 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Carl Hull for inquiries that concern Circulating Tumor Cells Inc by calling the company number (408) 719-6400, as your correspondence is most welcome. Additionally, the physical location of the single location of Circulating Tumor Cells Inc can be found at the coordinates 37.421573,-121.956161 as well as the street address 120 Baytech Drive in San Jose, California 95134.
For its online presence, you may visit Circulating Tumor Cells Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.